Literature DB >> 14505600

Quality of life in sleep disorders.

Marlene A Reimer1, W Ward Flemons.   

Abstract

Quality of life is a major outcome variable in choosing and evaluating treatment alternatives for sleep disorders. However, the number of well validated and sufficiently responsive quality of life measures for use with this population is limited. The SF-36, Nottingham Health Profile (NHP) and Sickness Impact Profile (SIP) are the most frequently used generic measures. The Functional Outcomes of Sleep Questionnaire (FOSQ) and Sleep Apnoea Quality of Life Index (SAQLI) are useful as condition/disease specific measures. However there are not yet specific measures in common use for other sleep disorders. Results across the sleep disorders that have been studied, primarily sleep apnea, narcolepsy, restless legs and insomnia, have consistently shown poorer quality of life than population norms prior to treatment, particularly in those dimensions related to sleep, energy and fatigue. Before treatment scorespes typically are of similar magnitude to those found among individuals with other chronic diseases such as hypertension and chronic obstructive pulmonary disease. With treatment quality of life scores may or may not improve to the level of population norms, suggesting that currently available treatments may not fully reverse the effects of the common sleep disorders.

Entities:  

Mesh:

Year:  2003        PMID: 14505600     DOI: 10.1053/smrv.2001.0220

Source DB:  PubMed          Journal:  Sleep Med Rev        ISSN: 1087-0792            Impact factor:   11.609


  69 in total

1.  CareWatch: A Home Monitoring System for Use in Homes of Persons With Cognitive Impairment.

Authors:  Meredeth Rowe; Stephen Lane; Chad Phipps
Journal:  Top Geriatr Rehabil       Date:  2007-01-01

2.  The face of sleepiness: improvement in appearance after treatment of sleep apnea.

Authors:  Ronald D Chervin; Deborah L Ruzicka; Arshia Vahabzadeh; Margaret C Burns; Joseph W Burns; Steven R Buchman
Journal:  J Clin Sleep Med       Date:  2013-09-15       Impact factor: 4.062

Review 3.  Risks of general anaesthesia in people with obstructive sleep apnoea.

Authors:  Cindy den Herder; Joachim Schmeck; Dick J K Appelboom; Nico de Vries
Journal:  BMJ       Date:  2004-10-23

4.  Is the severity of obstructive sleep apnea or the magnitude of respiratory effort associated with gastroesophageal reflux?

Authors:  Levent Ozturk; Zerrin Pelin
Journal:  World J Gastroenterol       Date:  2005-08-14       Impact factor: 5.742

5.  CPAP therapy in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea: does it offer a better quality of life and sleep?

Authors:  Charalampos Mermigkis; Izolde Bouloukaki; Katerina M Antoniou; Demetrios Mermigkis; Kostas Psathakis; Ioannis Giannarakis; Georgios Varouchakis; Nikolaos Siafakas; Sophia E Schiza
Journal:  Sleep Breath       Date:  2013-02-06       Impact factor: 2.816

6.  Evaluation of the safety of modafinil for treatment of excessive sleepiness.

Authors:  Thomas Roth; Jonathan R L Schwartz; Max Hirshkowitz; Milton K Erman; Jeffrey M Dayno; Sanjay Arora
Journal:  J Clin Sleep Med       Date:  2007-10-15       Impact factor: 4.062

7.  Long-Term Effectiveness and Safety of Maxillomandibular Advancement for Treatment of Obstructive Sleep Apnea.

Authors:  Scott B Boyd; Arthur S Walters; Peter Waite; Susan M Harding; Yanna Song
Journal:  J Clin Sleep Med       Date:  2015-07-15       Impact factor: 4.062

8.  Randomized controlled trial of pharmacological replacement of melatonin for sleep disruption in individuals with tetraplegia.

Authors:  Jamie M Zeitzer; Ban Ku; Doug Ota; B Jenny Kiratli
Journal:  J Spinal Cord Med       Date:  2013-10-24       Impact factor: 1.985

9.  Recognition and management of excessive sleepiness in the primary care setting.

Authors:  Jonathan R L Schwartz; Thomas Roth; Max Hirshkowitz; Kenneth P Wright
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2009

10.  The economic consequences of narcolepsy.

Authors:  Poul Jennum; Stine Knudsen; Jakob Kjellberg
Journal:  J Clin Sleep Med       Date:  2009-06-15       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.